KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Other financing activities (2018 - 2024)

Alnylam Pharmaceuticals (ALNY) has disclosed Other financing activities for 7 consecutive years, with -$1.8 million as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Other financing activities fell 121.24% year-over-year to -$1.8 million, compared with a TTM value of -$3.1 million through Dec 2025, changed N/A, and an annual FY2025 reading of $2.4 million, changed N/A over the prior year.
  • Other financing activities was -$1.8 million for Q3 2024 at Alnylam Pharmaceuticals, down from -$1.3 million in the prior quarter.
  • Across five years, Other financing activities topped out at $8.3 million in Q3 2023 and bottomed at -$16.3 million in Q4 2023.
  • Average Other financing activities over 5 years is $3.5 million, with a median of $4.2 million recorded in 2020.
  • The sharpest move saw Other financing activities soared 114.29% in 2022, then crashed 317.77% in 2023.
  • Year by year, Other financing activities stood at $4.2 million in 2020, then decreased by 16.67% to $3.5 million in 2021, then skyrocketed by 114.29% to $7.5 million in 2022, then plummeted by 317.77% to -$16.3 million in 2023, then skyrocketed by 89.16% to -$1.8 million in 2024.
  • Business Quant data shows Other financing activities for ALNY at -$1.8 million in Q3 2024, -$1.3 million in Q2 2024, and $3.1 million in Q1 2024.